In the News
The latest news reports, articles, and stories that may be of importance to leukemia and lymphoma patients, caregivers, and family members.
Published: September 18, 2018
Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food & Drug Administration said yesterday.... More >>.
Published: September 12, 2018
St. Jude Children's Research Hospital investigators have unraveled the origins and identified mutations with a perplexing form of acute leukemia, The landmark study appears today as an advance online publica ... More >>.
Published: August 09, 2018
Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy. About one-third of leukem ... More >>.
Published: August 07, 2018
As cost for cancer care skyrocket---projected to be $173 billion by 2020, a 39 percent increase from 2010. The Leukemia & Lymphoma Society (LLS) is renewing its call for action to ease the cost of cancer ... More >>.
Published: August 06, 2018
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The Universit ... More >>.
Published: July 20, 2018
Progress in treating acute myeloid leukemia (AML), a blood cancer that takes more than 10,000 lives in the United States each year, took an important step forward today with the U.S. Food Drug Administration ... More >>.
Published: July 20, 2018
Author: James Nam, PharmD
Determining the clinical stage of patients with chronic lymphocytic leukemia (CLL) may be an effective prognostic marker for time to next therapy (TTNT) and overall survival (OS), according to a study publis ... More >>.
Published: July 09, 2018
Author: Randi Hernandez
Using deep sequencing techniques, investigators of a study published in Nature determined they were able to tease out the predictors that are associated with the development of acute myeloid leukemi ... More >>.
Published: June 27, 2018
UCLA researchers have developed synthetic T lymphocytes, or T cells, that are near-perfect facsimiles of human T cells. The ability to create the artificial cells could be a key step toward more effective dr ... More >>.
Published: June 25, 2018
Author: Alexander M. Castellino, PhD
A long-term follow-up of the ENEST freedom study reported that 96 weeks after stopping treatment, nearly half (48.9%) of patients with chronic myeloid leukemia (CML) with front-line treatment with nilotinib ... More >>.